Zacks Research Downgrades Rhythm Pharmaceuticals to Strong Sell

Rhythm Pharmaceuticals (NASDAQ: RYTM) faced a significant downgrade from Zacks Research, moving from a “hold” rating to a “strong sell” rating, as reported on Monday. This change reflects an evolving sentiment among analysts regarding the company’s performance and potential in the market.

Several analysts have recently offered varying perspectives on Rhythm Pharmaceuticals. Needham & Company LLC raised their target price for the company’s shares from $145.00 to $148.00 and maintained a “buy” rating in a report released on January 9, 2024. Similarly, UBS Group reaffirmed a “buy” rating on December 17, 2023. HC Wainwright also increased their target price from $123.00 to $125.00 while retaining a “buy” rating.

Conversely, Citizens Jmp adjusted their target price for Rhythm Pharmaceuticals from $141.00 to $167.00, granting the stock a “market outperform” rating on December 12, 2023. Notably, Wall Street Zen downgraded Rhythm from a “hold” rating to a “sell” on November 8, 2023. Currently, one analyst rates the stock as a Strong Buy, while fifteen have given it a Buy rating, one has assigned a Hold rating, and two analysts have issued Sell ratings. According to data from MarketBeat.com, Rhythm Pharmaceuticals holds an average rating of “Moderate Buy” with a consensus price target of $131.29.

Recent Earnings Report and Insider Activity

On November 4, 2023, Rhythm Pharmaceuticals released its quarterly earnings results, reporting a loss of $0.82 earnings per share, which fell short of analysts’ expectations of $0.72 by $0.10. The company generated $51.30 million in revenue for the quarter, surpassing the consensus estimate of $50.71 million. Despite these figures, the company recorded a negative return on equity of 433.21% and a negative net margin of 110.32%. Analysts project that Rhythm Pharmaceuticals will post an EPS of -4.32 for the current fiscal year.

In addition to the earnings report, insider trading activity has also drawn attention. Insider Joseph Shulman sold 9,748 shares of Rhythm’s stock on October 30, 2023, at an average price of $115.24, totaling approximately $1.12 million. Following this transaction, Shulman retained 8,509 shares, valued at about $980,577. This sale represented a significant decrease of 53.39% in his holdings.

Another insider, Pamela J. Cramer, sold 3,350 shares on December 11, 2023, at an average price of $111.00, amounting to $371,850. After this sale, she owned 20,814 shares valued at $2.31 million, marking a 13.86% reduction in her position. Over the last quarter, insiders sold a total of 15,913 shares worth approximately $1.82 million. Currently, corporate insiders hold 6.10% of the company’s stock.

Institutional Investment Trends

Recent changes in institutional holdings further reflect the evolving landscape for Rhythm Pharmaceuticals. Smartleaf Asset Management LLC increased its stake in the company by 97.2% during the third quarter, now owning 286 shares valued at $29,000. Farther Finance Advisors LLC raised its holdings by an impressive 1,110.3%, owning 351 shares worth $35,000 after acquiring an additional 322 shares.

GAMMA Investing LLC also boosted its stake by 48.6%, now holding 361 shares valued at $39,000. Optiver Holding B.V. increased its holdings by 65.2%, acquiring 365 shares worth $37,000. Osaic Holdings Inc. enhanced its position by 65.9%, now owning 979 shares valued at $62,000.

Rhythm Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to developing targeted therapies for rare genetic diseases related to obesity and metabolic dysfunction. The company’s research primarily focuses on the melanocortin-4 receptor (MC4R) pathway, crucial for regulating appetite, energy expenditure, and body weight. Their lead investigational product, setmelanotide, is designed to restore signaling in patients with specific genetic deficiencies.